Zentalis shares first OS data for azenosertib in ovarian cancer
Zentalis Pharmaceuticals has published the first overall survival data for its investigational WEE1 inhibitor azenosertib, drawn from an interim analysis of the DENALI Part 1b study in platinum-resistant ovarian cancer. The results appear in an abstract ahead of a rapid oral presentation at the European Society for Medical Oncology Congress in Madrid on 23 October 2026.
The data, from a September 2025 cutoff, show a median OS of 15.8 months (95% CI, 8.7 to 17.8) in the Cyclin E1-positive subgroup of 48 patients, compared with 7.5 months (95% CI, 5.8 to 12.3) in the 46 Cyclin E1-negative patients. No new safety signals were identified. Zentalis said the OS figures compare favourably to historical benchmarks for single-agent chemotherapy in this setting, though it did not name a specific comparator dataset or provide a formal comparative analysis.
Trial design and biomarker strategy
DENALI Part 1b enrolled 102 patients with platinum-resistant ovarian cancer, all of whom received prior bevacizumab, and administered azenosertib at 400 mg once daily on a five-days-on, two-days-off schedule. The primary endpoint was objective response rate; OS was a secondary endpoint. Cyclin E1 status was determined retrospectively by immunohistochemistry using a proprietary cutoff developed by Zentalis, with 94 of the 102 patients evaluable for biomarker analysis.
The company positions Cyclin E1 protein overexpression as a highly selective and predictive biomarker for response to WEE1 inhibition. Approximately half of all platinum-resistant ovarian cancer patients are estimated to be Cyclin E1-positive, a population for which no biomarker-specific approved therapy currently exists. That unmet need is the commercial and clinical rationale underpinning Zentalis's registration strategy for azenosertib.
Regulatory path and competitive landscape
The DENALI programme is registration-intended. Part 2, which prospectively enrols Cyclin E1-positive patients, is designed to support accelerated approval from the US FDA, subject to positive outcomes and agency alignment. Enrolment in the 100-patient Part 2b expansion cohort is complete, and Part 2c, which adds approximately 40 patients previously treated with a taxane, is currently enrolling. In parallel, the Phase 3 ASPENOVA trial is randomising roughly 420 Cyclin E1-positive patients against investigator's choice of standard-of-care chemotherapy, with progression-free survival as the primary endpoint and full approval as the longer-term goal.
WEE1 inhibition has attracted sustained industry interest as a mechanism that exploits replication stress in cancer cells with high genomic instability. Azenosertib is not the first WEE1 inhibitor to enter the clinic; AstraZeneca's adavosertib was an earlier entrant but was discontinued after a mixed clinical record. Zentalis is therefore developing azenosertib into a market where the mechanistic rationale is established but clinical differentiation and a reliable patient-selection strategy remain critical. The Cyclin E1 biomarker, if validated in the prospective DENALI Part 2 and ASPENOVA data, could provide the kind of companion-diagnostic anchor that regulators and payers increasingly expect for targeted oncology approvals.
Full results from DENALI Part 1b, including objective response rate and progression-free survival data, are expected to be presented at ESMO on 23 October. Investors and oncologists will scrutinise the mature OS readout, the safety profile at the selected 400 mg dose, and any signal on duration of response before drawing firm conclusions about azenosertib's prospects in a field where multiple PARP inhibitors and antibody-drug conjugates have already reshaped the treatment algorithm for ovarian cancer.